Novel Rx
SKIPPAIN Trial: Dr. Sheila Reyes
Dr. Sheila Reyes reviews abstract #0899 presented at the 2020 ACR annual meeting.
Improving Response to Pegloticase: Dr. Nicola Dalbeth
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952.
Nomenclature, Uveitis and Other Spondyloarthritis Features: Dr. Lianne Gensler
Dr. Gensler reviews her top selections for ACR 2020 today, including abstract #0881 and #0876. She also highlighted the study group on spondyloarthritis, which focused on nomenclature.
Combo Therapy v Monotherapy (SEAM-RA Trial): Dr. Richard Conway
Dr. Conway discusses ACR abstract #0939 presented Saturday at the 2020 ACR annual meeting.
Treatment of Dermatomyositis Studies: Dr Robert Chao
Dr. Robert Chao reviews two important abstracts - #0955 (IVIg) and #0958 (tocilizumab) - on the treatment of dermatomyositis as presented at the 2020 ACR annual meeting.
What is the SEAMless transition from combination Etanercept to Methotrexate? Dr. Jonathan Kay
Dr. Jonathan Kay takes a deep dive into plenary abstract #0939 presented at the ACR 2020 annual meeting, reviewing two previous clinical trials that also looked at this question and offering his perspective.
Staying on Therapy in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0804 - Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands- presented at the ACR 2020 annual meeting.
Improving Drug Adherence in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0799 presented Saturday at the ACR 2020 annual meeting.
SEAM-RA Trial: Dr. Jeff Curtis
Dr. Jeff Curtis discusses abstract #0939, which looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at ACR 2020.
Treatment Options for Psoriatic Arthritis: Dr Robert Chao
Dr. Robert Chao discusses abstracts #0375 and #0381 as presented Friday at the ACR 2020 annual meeting.
Poster Hall